JAMA Surg: FOLFIRINOX or GA first-line treatment of limited pancreatic catheter adenocarcinoma.
-
Last Update: 2020-07-28
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Fluorouresy, calcium zolinalate, Ilitikon, Oshariplatin and Gixithabin combined with yewol are the first-line chemotherapy programs for pancreatic cancerRecently, researchers compared or first-line treatment of limited pancreatic catheter adenocarcinoma efficacyPatients with previously untreated limited pancreatic catheter adenocarcinoma participated in the study in which patients received at least one cycle or treatment of the groupThe main endpoints of the study were excision rate, imaging indicators (reaction assessment criteria for solid tumors), serological indicators (serum cancer antigen levels), and total survival rates after chemotherapyMale name in the patientPatients receiving treatment had a lighter median age: older and higher rates of points or below had greater aggressive tumorsThe adjusted study found that the difference between the or the patient's objective serological and radiological response indicators was not significant, but the proportion of patients in the treatment group (in patients in case) achieved partial reactions was higher than in the only cases in the groupThe proportion of patients receiving radiotherapy in the group was higher, but the overall survival risk ratio of patients with both options was similarThe study concluded that the total survival rate of patients with limited pancreatic cancer received or used as a first-line chemotherapy regimen was similar, but the group response rate and pancreatic excision rate were higher
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
